FDA Drops the Heart, Breast Cancer and Dementia Boxed Warnings From Three Estradiol Patches. The Endometrial Cancer Warning Stays.
The FDA relabeled Minivelle, Vivelle and Vivelle-Dot on Oct. 30, bringing updated hormone products to nine. The endometrial cancer box still stands.
On Oct. 30, the Food and Drug Administration approved updated labeling for three estradiol transdermal patches, Minivelle, Vivelle and Vivelle-Dot, removing cardiovascular disease, breast cancer and probable dementia statements from their boxed warnings while keeping the warning on endometrial cancer with unopposed estrogen.
The patches come from two applicants, according to Contemporary OB/GYN, which reported the change from an HHS announcement the same day. It follows the agency's February action on six other menopausal hormone therapy products. Our earlier interview with Dr. David Borenstein on the first round of label changes covers the background.
Which products have new labels?
Nine so far. The FDA's list of menopausal hormone therapies with updated prescribing information, current as of Oct. 30, groups them by type: progestogen alone (Prometrium), systemic estrogen alone (Divigel, Cenestin, Enjuvia, Minivelle, Vivelle and Vivelle-Dot), topical vaginal estrogen (Estring) and combined estrogen and progestogen (Bijuva). The three patches are the new additions. Healio reported that 29 companies have submitted proposed label changes since November 2025, so most products have not yet been updated.
What the label actually says
Coverage described the action as removing the black box warning. The label is more specific than that. In The Script Pad's reading of the revised Minivelle prescribing information, the boxed warning is now limited to endometrial cancer with unopposed estrogen in women with a uterus. The Recent Major Changes section, dated 10/2026, lists revisions to the boxed warning and to the cardiovascular disorders and malignant neoplasms warnings, and lists the probable dementia warning as removed. The remaining box notes that adding a progestogen reduces the risk of endometrial hyperplasia and calls for adequate diagnostic workup, including endometrial sampling when indicated, for abnormal bleeding. One quirk: the table of contents in the same document still carries the old four-part warning title, so a quick skim can mislead. The contraindications section was also revised in October.
The contraindications remain substantial. They still include abnormal genital bleeding of unknown cause, breast cancer or a history of it, estrogen-dependent neoplasia, active or prior deep vein thrombosis or pulmonary embolism, active or prior arterial thromboembolic disease such as stroke or myocardial infarction, hepatic impairment and known thrombophilic disorders. The warnings section still says increased risks of pulmonary embolism, deep vein thrombosis and stroke are reported with systemic estrogen therapy.
The box got smaller, not empty. A patient with a uterus still needs a progestogen plan, and breast cancer and thromboembolic disease remain contraindications.
Is there a patch shortage?
Not officially. The FDA said it is "not aware of an imminent risk of a nationwide shortage" and is working with all six manufacturers of approved estradiol patches, whose output has roughly doubled over the past 12 months, Contemporary OB/GYN reported. Reuters, in a report republished by AOL, quoted Sarah Ibrahim, deputy center director for regulatory programs at the FDA's drug center, as saying the agency has expedited review of 10 manufacturing supplements this year, two in the past week. Reuters also noted that the FDA has not designated patches as in shortage, and that some injectable and vaginal estrogen products have also been hard to find. The FDA is exploring over-the-counter vaginal estrogen with sponsors, which would require a separate approval. For another source of patch supply, see our report on the first generic Climara Pro.
What it means in clinic
Expect patients to ask whether the patch is now considered safe. The accurate answer is that the label no longer leads with cardiovascular, breast cancer and dementia statements, but the contraindications and the endometrial cancer warning remain, and the decision is still individual. Susan Reed, MD, MPH, of UW Medicine, told Contemporary OB/GYN that removal of the warnings "makes it the clinician's responsibility to understand risks for special populations." When a pharmacy cannot fill a specific patch, the FDA notes that patches are only one option, so it is worth documenting an acceptable alternative strength, brand or route in advance.
Reported, fact-checked and edited by The Script Pad's editorial staff. See How we use AI.
This article is for professional education and does not replace clinical judgment. Treatment decisions should be based on the individual patient and current guidelines.
